NeoTIL in Advanced Solid Tumors
NeoTIL in Advanced Solid Tumors
Single center, single arm pilot trial to test the feasibility, safety and efficacy of
 NeoTIL-ACT combined with low-dose irradiation (LDI) in patients with advanced, recurrent or
 metastatic solid tumors.

 The trial is based on lymphodepleting chemotherapy followed by LDI, and then ACT utilizing ex
 vivo expanded TIL, enriched for tumor antigen specificity (NeoTIL), in combination with high
 dose Interleukin-2 (IL-2) (optional, depending on patient's tolerance).

 LDI will be administered once to metastatic lesions using tomotherapy.
The objective of the trial is to define the feasibility, safety, and efficacy of NeoTIL-ACT
 in combination with LDI in patients with advanced, recurrent or metastatic solid tumors, as
 categorized in two molecularly defined cohorts.

 Study treatment will begin with intravenous (IV) non-myeloablative (NMA) lymphodepleting
 chemotherapy composed by fludarabine and cyclophosphamide. Both treatments will be started on
 the same day. Fludarabine will be administered from for five days, and cyclophosphamide ffor
 two days. Low-dose irradiation (LDI) will be administered once, to tumor lesions using
 tomotherapy.

 Patients will receive NeoTIL infusion intravenously followed by high dose IL-2 administration
 every eight hours, for a maximum of eight doses. Supportive care will be given as needed
 during the whole treatment period.

 Patients achieving a stable disease, partial response or complete response after NeoTIL-ACT
 treatment will then enter a clinical follow-up period for 5 years.
Inclusion Criteria:

 1. Patients with advanced (not radically treatable), recurrent or metastatic solid tumors
 of any histology with the exception of primary central nervous system tumors, who have
 received, and then progressed or been intolerant to at least one standard therapy
 regimen in the advanced or metastatic setting if such a therapy exists, and have been
 considered for all other potentially efficacious therapies prior to enrollment. If the
 participant refuses, or is not eligible for these regimens in the opinion of the
 investigator, the reason must be documented in the medical record.

 2. Patients who have previously undergone tumor resection or biopsy and for whom
 pre-Rapid Expansion Protocol (REP) NeoTIL cultures are ongoing or completed.

 3. At least one lesion accessible to biopsy for translational research (TR) at baseline
 and D30, without putting the patient at unusual risk.

 4. Male or female age ≥ 18 to ≤ 70 years at the time of informed consent. Patients aged
 >70 will be evaluated by the investigator, and decision will be made according to
 patient's status, upon agreement with the PI.

 5. Clinical performance status of Eastern Cooperative Oncology Group (ECOG) of 0 to 2.

 6. Life expectancy of greater than 12 weeks.

 7. Radiologically measurable disease (as per Response Evaluation Criteria in Solid
 Tumours [RECIST] v1.1).

 1. Modified RECIST should be used for mesothelioma

 2. Prostate Cancer Working Group 3 (PCWG3) criteria should be used for prostate
 cancer

 8. Adequate serology defined by the following laboratory results:

 1. Negative test for Human Immunodeficiency Virus (HIV)

 2. Patients with active or chronic hepatitis B (defined as having a positive
 hepatitis B surface antigen [HBsAg] test at pre-screening) are not eligible.

 -  Patients with past/resolved Hepatitis B virus (HBV) infection (defined as
 having a negative HBsAg test and a positive antibody to hepatitis B core
 antigen (anti-HBc) antibody test) are eligible, if HBV deoxyribonucleic acid
 (DNA) test is negative.

 -  HBV DNA must be obtained in patients with positive hepatitis B core antibody
 prior start of study treatment.

 3. Patients with active hepatitis C are not eligible. Patients positive for
 Hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction
 (PCR) is negative for HCV ribonucleic acid (RNA).

 9. Hematology

 1. Absolute neutrophil count ≥ 1.0 x 109 cell/L without the support of granulocyte
 colony stimulating factor (G-CSF).

 2. Platelet count ≥ 100 x109 cell/L

 3. Hemoglobin ≥ 80 g/L. Subjects may be transfused to reach this cut-off.

 10. Coagulation

 a. International normalization ratio (INR) ≤1.5 times the upper limit of normal (x
 ULN) unless the subject is receiving anticoagulant.

 i) Exception: for patients with hepatocellular carcinoma (HCC), the INR may be up to
 2.2, as long as the Child-Pugh score is A6 maximum.

 b. Partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) ≤
 1.5 x ULN unless the subject is receiving anticoagulant therapy.

 11. Chemistry:

 1. Serum alanine transaminase (ALT) / aspartate aminotransferase (AST) ≤ to 3 x ULN
 i) Exception: ALT/AST considered related to liver metastasis ≤ to 5 x ULN ii)
 Exception: for patients with HCC serum ALT/AST ≤ to 5 x ULN

 2. Total bilirubin ≤1.5 x ULN i) Exception: in patients with Gilbert's syndrome who
 must have a total bilirubin ≤2.5 x ULN ii) Exception: total bilirubin considered
 related to liver metastasis ≤3 x ULN iii) Exception: for patients with HCC total
 bilirubin ≤2.3 x ULN, as long as the Child-Pugh score is A6 maximum

 3. Creatinine clearance by Cockcroft-Gault formula ≥ 40 ml/min

 12. Adequate cardiovascular function, with documented left ventricular ejection fraction
 (LVEF) ≥ 45%. This parameter must be documented within 12 weeks before registration

 13. Adequate respiratory function with forced expiratory volume in 1 second (FEV1) ≥ 50%
 predicted, forced vital capacity (FVC) ≥ than 50% predicted and diffusing capacity for
 carbon monoxide (DLCO) ≥ than 50% predicted corrected. Patients with lung cancer or
 mesothelioma and values slightly under these limits (but >30% of predicted) can be
 enrolled after discussion and approval by the PI. These parameters must be documented
 within 12 weeks before registration

 14. At the time the patient receives the NMA chemotherapy regimen (D-7):

 1. ≥14 days or 5 half-lives must have elapsed from any chemotherapeutic cytotoxic
 drug, whichever is shorter.

 2. ≥28 days must have elapsed from bevacizumab, aflibercept and other
 anti-angiogenic antibodies

 3. ≥28 days or 5 half-lives (whichever is shorter) must have elapsed from a
 non-cytotoxic drug including but not limited to trastuzumab, pertuzumab, and
 other molecular targeted therapy (such as tyrosine kinase inhibitors, etc…) i)
 Note: In case of probable tumor flare upon stopping of the non-cytotoxic drug,
 the investigator may decide to shorten this delay, upon agreement of the
 Principal Investigator (PI), in a case-by-case approach.

 4. ≥21 days must have elapsed from the last antibody therapy that could affect an
 anti-cancer immune response, including but not limited to anti-Cytotoxic
 T-lymphocyte-associated protein 4 (CTLA4), anti-Programmed cell death protein 1
 (PD-1), anti-Programmed death-ligand 1 (PD-L1), anti-Tumor Necrosis Factor
 Receptor Superfamily, member 4 (OX-40), or anti-Lymphocyte-activation gene 3
 (LAG3) antibody therapy or their combination

 5. Exceptions: denosumab and biphosphonates are permitted (and will be administered
 as standard of care [SOC]).

 6. Exceptions: androgen-deprivation therapy (ADT) for prostate cancer and hormonal
 therapy for breast cancer are permitted (and will be administered as SOC).

 15. Patients' toxicities from previous therapies must have recovered to at least grade 1
 according to National Cancer Institute Common Terminology Criteria for Adverse v5.0
 (NCI CTCAE v5.0), except for toxicities described below, as long as they do not put at
 risk the patient's condition and do not require systemic immunosuppressive steroids at
 immunosuppressive doses, including but not limited to:

 -  Fatigue

 -  Alopecia

 -  Skin disorders

 -  Stable neuropathy

 -  Endocrinopathies requiring replacement treatment Note: For other medical
 conditions, or for any other toxicity with a higher grade but controlled by
 adequate treatment, prior discussion and agreement with the PI is mandatory.

 Note: Patients may have undergone surgical procedures within the past 3 weeks, as long
 as all toxicities have recovered to grade 1 or less.

 16. For women of childbearing potential (WOCBP: sexually mature women who have not
 undergone a hysterectomy and/or bilateral oophorectomy, have not been naturally
 post-menopausal for at least 12 consecutive months or have a serum
 follicle-stimulating hormone (FSH) < 40 milli-International Unit [mIU]/ml):

 1. Agreement to follow instructions for method(s) of contraception for the couple,
 from screening until month 6 post start of NMA chemotherapy of the study.

 2. Negative pregnancy test (urine or serum) during screening

 17. For men participating in the trial and their female partners: agreement to follow
 instructions for method(s) of contraception for the couple from screening until month
 6 post start of NMA chemotherapy of the study.

 Exclusion Criteria:

 1. Patients with an active second malignancy, except for

 1. non-melanoma skin cancer that has been apparently cured or successfully resected

 2. carcinoma in situ as long as they have been adequately treated

 3. Any malignancy that can be adequately managed expectantly without compromising
 prognosis, and after PI agreement.

 Patients who have a history of malignancy are not considered to have an active
 malignancy if they have completed therapy since at least 2 years and are considered by
 their treating investigator to be at ≤ 30% risk for relapse.

 2. Patients with symptomatic and/or untreated brain metastases. Patients with
 definitively-treated brain metastases will be considered for enrollment after
 agreement with PI, as long as lesions are stable for ≥ 14 days prior to beginning the
 chemotherapy, there are no new brain lesions, and the patient does not require ongoing
 corticosteroid treatment.

 3. Patients with known peritoneal metastases who have a recent history of intermittent
 bowel obstruction (even partial), unless such obstruction has been resolved. Agreement
 with the PI is mandatory.

 4. Patients with leptomeningeal carcinomatosis

 5. History of idiopathic pulmonary fibrosis or evidence of active pneumonitis (any
 origin)

 6. History of recent myocardial infarction or unstable angina, either within six months
 of enrolment

 7. Documented Child-Pugh score of B or C for hepatocellular carcinoma patients with known
 underlying liver dysfunction

 8. Active severe systemic infections within four weeks prior to beginning of NMA
 chemotherapy.

 9. Patient requiring regular systemic immunosuppressive therapy (for example for organ
 transplantation, chronic rheumatologic disease); all immunosuppressive medications
 including but not limited to steroids, mycophenolate mofetil, azathioprine,
 methotrexate, thalidomide, and anti-tumor necrosis factor-alpha (TNF-alpha) agents
 must have been discontinued within the last two weeks prior to starting NMA
 chemotherapy.

 1. Note: Use of inhaled or topical steroids or corticosteroid use for radiographic
 procedures is permitted

 2. Note: The use of physiologic corticosteroid replacement therapy is permitted.

 10. History of severe immediate hypersensitivity reaction to any of the agents used in
 this study.

 11. Women who are pregnant or breastfeeding because of the potentially dangerous effects
 of the treatment on the fetus or infant.

 12. Subjects for whom there are concerns that they will not reliably comply with the
 requirements for contraception should not be enrolled into the study.

 13. Any serious underlying medical condition that could interfere with study medication
 and potential adverse events.

 14. Any mental or other impairment that may compromise compliance with the requirements of
 the study.

 15. Patient participation in any other study currently receiving treatment. If the patient
 is in the follow-up period, he/she may be enrolled, as far as the elapsed time since
 the last previous treatment administration and the preparative regimen (NMA
 chemotherapy) is respected according to Inclusion Criteria n°14.

 16. Participation in a research project using radiation sources exceeding an effective
 dose of 5 millisievert (mSv) with no direct benefit within the 12 last months.